Abstract
IntroductionThe introduction of high-throughput technologies, also called -omics technologies, into epidemiology has raised the need for high-quality observational studies to reduce several sources of error and bias.MethodsThe Norwegian Women and Cancer (NOWAC) postgenome cohort study consists of approximately 50,000 women born between 1943 and 1957 who gave blood samples between 2003 and 2006 and filled out a two-page questionnaire. Blood was collected in such a way that RNA is preserved and can be used for gene expression analyses. The women are part of the NOWAC study consisting of 172,471 women 30 to 70 years of age at recruitment from 1991 to 2006 who answered one to three questionnaires on diet, medication use, and lifestyle. In collaboration with the Norwegian Breast Cancer Group, every NOWAC participant born between 1943 and 1957 who is admitted to a collaborating hospital for a diagnostic biopsy or for surgery of breast cancer will be asked to donate a tumor biopsy and two blood samples. In parallel, at least three controls are approached for each breast cancer case in order to obtain blood samples from at least two controls per case. The controls are drawn at random from NOWAC matched by time of follow-up and age. In addition, 400 normal breast tissues as well as blood samples will be collected among healthy women participating at the Norwegian Mammography Screening program at the Breast Imaging Center at the University Hospital of North-Norway, Tromsø.ResultsThe NOWAC postgenome cohort offers a unique opportunity (a) to study blood-derived gene expression profiles as a diagnostic test for breast cancer in a nested case-control design with adjustment for confounding factors related to different exposures, (b) to improve the reliability and accuracy of this approach by adjusting for an individual's genotype (for example, variants in genes coding for hormone and drug-metabolizing and detoxifying enzymes), (c) to study gene expression profiles from peripheral blood as surrogate tissue to biomonitor defined exposure (for example, hormone) and its association with disease risk (that is, breast cancer), and (d) to study gene variants (single nucleotide polymorphisms and copy number variations) and environmental exposure (endogenous and exogenous hormones) and their influence on the incidence of different molecular subtypes of breast cancer.ConclusionThe NOWAC postgenome cohort combining a valid epidemiological approach with richness of biological samples should make an important contribution to the study of the etiology and system biology of breast cancer.
Highlights
The introduction of high-throughput technologies, called -omics technologies, into epidemiology has raised the need for high-quality observational studies to reduce several sources of error and bias
The Norwegian Women and Cancer (NOWAC) postgenome cohort offers a unique opportunity (a) to study blood-derived gene expression profiles as a diagnostic test for breast cancer in a nested case-control design with adjustment for confounding factors related to different exposures, (b) to improve the reliability and accuracy of this approach by adjusting for an individual's genotype, (c) to study gene expression profiles from peripheral blood as surrogate tissue to biomonitor defined exposure and its association with disease risk, and (d) to study gene variants and environmental exposure and their influence on the incidence of different molecular subtypes of breast cancer
The NOWAC postgenome cohort combining a valid epidemiological approach with richness of biological samples should make an important contribution to the study of the etiology and system biology of breast cancer
Summary
The introduction of high-throughput technologies, called -omics technologies, into epidemiology has raised the need for high-quality observational studies to reduce several sources of error and bias. Observational epidemiologic data are used as major criteria to categorize any chemicals or lifestyle factors as carcinogenic. This is an inherent part of the carcinogen classification as carried out by the World Health Organization through its cancer research center at the International Agency for Research on Cancer in Lyon, France [1]. CNV = copy number variation; DCIS = ductal carcinoma in situ; GWA = genome-wide association; HT = hormone therapy; NOWAC = Norwegian Women and Cancer (study); SHD = the Directorate of Health and Social affairs; SNP = single nucleotide polymorphism. Hundreds of thousands of probes spotted either on a glass slide or on beads allow whole-genome scans of single nucleotide polymorphisms (SNPs) and copy number variations (CNVs) for each individual. It should be noted that, due to the effect of RNases, which degrade RNA unless stabilized into a specific buffer, standard biobanks do not provide high-quality mRNA
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
